The primary outcome was symptomatic remission at 6 weeks (short Crohn’s disease activity index—sCDAI <150), and key secondary outcomes were calprotectin response (<250 ug/g and reduction by >50% of for those with baseline calprotectin >250 ug/g) and c-reactive protein (CRP) response (<5 mg/L and reduction by >50% of for those with baseline CRP >5 mg/L). This evidence concerns the gene CRP and Crohn disease.